Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Australian Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 27 Jun 2026	AU$164.7b	AU$78.6b	AU$2.0b	24.9x	82.8x	2.1x
Mon, 25 May 2026	AU$150.6b	AU$77.8b	AU$1.8b	24.6x	83.7x	1.9x
Wed, 22 Apr 2026	AU$175.3b	AU$77.7b	AU$1.9b	26.9x	90.2x	2.3x
Fri, 20 Mar 2026	AU$168.3b	AU$78.1b	AU$2.0b	24.2x	85.3x	2.2x
Sun, 15 Feb 2026	AU$184.9b	AU$72.2b	AU$2.1b	33.8x	88x	2.6x
Tue, 13 Jan 2026	AU$215.5b	AU$73.8b	AU$4.5b	32x	48x	2.9x
Thu, 11 Dec 2025	AU$219.6b	AU$74.1b	AU$4.5b	33.3x	48.9x	3x
Sat, 08 Nov 2025	AU$221.6b	AU$75.0b	AU$4.6b	32.9x	47.9x	3x
Mon, 06 Oct 2025	AU$242.7b	AU$74.5b	AU$4.6b	30.4x	53.3x	3.3x
Wed, 03 Sep 2025	AU$240.7b	AU$75.0b	AU$4.6b	32x	52.3x	3.2x
Fri, 01 Aug 2025	AU$277.5b	AU$70.5b	AU$4.9b	38.2x	56.8x	3.9x
Sun, 29 Jun 2025	AU$251.6b	AU$71.7b	AU$4.3b	26x	59x	3.5x
Tue, 27 May 2025	AU$258.2b	AU$71.8b	AU$4.3b	27.4x	60.6x	3.6x
Thu, 24 Apr 2025	AU$245.4b	AU$70.6b	AU$4.9b	27.1x	50.2x	3.5x
Sat, 22 Mar 2025	AU$255.5b	AU$71.1b	AU$4.9b	28.2x	52x	3.6x
Mon, 17 Feb 2025	AU$239.0b	AU$66.0b	AU$3.6b	28.8x	67.3x	3.6x
Wed, 15 Jan 2025	AU$245.8b	AU$66.5b	AU$3.3b	23.8x	74.9x	3.7x
Fri, 13 Dec 2024	AU$242.9b	AU$68.2b	AU$3.3b	26.4x	74.1x	3.6x
Sun, 10 Nov 2024	AU$242.2b	AU$67.7b	AU$3.2b	25.5x	76.7x	3.6x
Tue, 08 Oct 2024	AU$241.5b	AU$66.9b	AU$3.0b	29.5x	79.3x	3.6x
Thu, 05 Sep 2024	AU$240.3b	AU$66.3b	AU$3.1b	26.5x	77.8x	3.6x
Sat, 03 Aug 2024	AU$242.8b	AU$63.3b	AU$2.7b	29.6x	90x	3.8x
Mon, 01 Jul 2024	AU$237.4b	AU$62.7b	AU$2.6b	32.1x	90.8x	3.8x
Wed, 29 May 2024	AU$224.3b	AU$61.0b	AU$2.6b	27.9x	85.3x	3.7x
Fri, 26 Apr 2024	AU$222.5b	AU$61.6b	AU$2.7b	26.7x	82.9x	3.6x
Sun, 24 Mar 2024	AU$222.2b	AU$61.8b	AU$2.7b	26.2x	83x	3.6x
Tue, 20 Feb 2024	AU$221.4b	AU$60.5b	AU$3.5b	25.6x	63.7x	3.7x
Thu, 18 Jan 2024	AU$223.3b	AU$60.5b	AU$2.9b	24.9x	78x	3.7x
Sat, 16 Dec 2023	AU$218.9b	AU$60.0b	AU$2.8b	24.8x	78.1x	3.6x
Mon, 13 Nov 2023	AU$200.5b	AU$61.2b	AU$3.0b	24.5x	67.1x	3.3x
Wed, 11 Oct 2023	AU$201.9b	AU$61.1b	AU$2.9b	25x	69.1x	3.3x
Fri, 08 Sep 2023	AU$208.9b	AU$61.4b	AU$2.9b	25.5x	71.7x	3.4x
Sun, 06 Aug 2023	AU$210.2b	AU$58.1b	AU$2.9b	26.1x	71.5x	3.6x
Tue, 04 Jul 2023	AU$216.3b	AU$57.8b	AU$2.9b	27.6x	74.7x	3.7x

Current Industry PE

Investors are optimistic on the Australian Healthcare industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 83.6x which is higher than its 3-year average PE of 70.7x.

The 3-year average PS ratio of 3.3x is higher than the industry's current PS ratio of 2.1x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have declined 12% per year over the last three years.
Meanwhile revenues for these companies have grown 11% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Australian Healthcare sector?


AU Market	-0.91%
Healthcare	1.13%
Healthtech	8.47%
Healthcare Services	2.23%
Medical Equipment	0.30%
Life Sciences	-1.05%
Biotech	-1.24%
Pharma	-6.55%

Industry PE

Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 2kx.

Analysts are expecting annual earnings growth of 3.7%, which is lower than the prior year's growth of 92.7% per year.

Forecasted Growth

Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 50% over the next 5 years.
This is better than its past earnings decline of 60% per year.

In contrast, the Healthtech industry is expected to see its earnings grow by 3.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
PME Pro Medicus	AU$188.88	9.3% +AU$1.7b	-32.7%	PE84.1x
RHC Ramsay Health Care	AU$43.10	9.1% +AU$830.0m	19.3%	PE36.3x
TLX Telix Pharmaceuticals	AU$15.33	5.7% +AU$281.7m	-37.3%	PS4.5x
ANN Ansell	AU$31.47	4.9% +AU$206.1m	3.6%	PE22.3x
SHL Sonic Healthcare	AU$20.42	1.8% +AU$182.8m	-23.5%	PE18.7x

Racura Oncology Doses First Patient in Harness-1 Phase 1A/B Trial of Rc220 in Combination with Osimertinib for Egfr-Mutant Non-Small Cell Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance. The first patient received RC220 at 50 mg/m2 by intravenous infusion. No adverse events were observed. HARNESS-1 is designed to test whether RC220, Racura's proprietary formulation of (E,E)-bisantrene, can be safely combined with osimertinib (Tagrisso; AstraZeneca), a third-generation EGFR tyrosine kinase inhibitor (TKI) and standard-of-care therapy for EGFR-mutant NSCLC to delay or prevent TKI treatment resistance. Although EGFR TKIs have transformed outcomes for many patients with EGFR-driven lung cancer, acquired treatment resistance remains a central therapeutic challenge. EGFR-mutant NSCLC is a molecularly stratified lung adenocarcinoma subtype driven by constitutive EGFR kinase signaling and initial sensitivity to EGFR inhibition. However, responses to EGFR tyrosine kinase inhibitors, including osimertinib, are typically limited by acquired resistance, arising through heterogeneous mechanisms such as secondary EGFR alterations, bypass receptor tyrosine kinase activation, MAPK/PI3K pathway reactivation, oncogenic fusions, lineage plasticity, epithelial-to-mesenchymal transition and histologic transformation. RC220 is being developed to target the non-canonical G-quadruplex DNA and RNA structures enriched in oncogenic regulatory regions, including promoters, untranslated regions and highly transcribed loci. Stabilization of these structures can disrupt transcriptional and post-transcriptional control networks that sustain malignant proliferation, including silencing the c-MYC-regulated growth and survival pathways. HARNESS-1 is designed to evaluate the safety and tolerability of RC220 with continued osimertinib-mediated EGFR suppression, while generating pharmacokinetic, pharmacodynamic, molecular response and translational biomarker data. HARNESS-1 is a multi-center Phase 1a/b clinical study in patients with EGFR-mutant NSCLC receiving osimertinib. The study includes an observational screening stage using ctDNA to help identify eligible patients and characterize tumor molecular status before treatment. The Phase 1a dose-escalation stage will evaluate RC220 administered by intravenous infusion on Day 1 of each 21-day cycle in combination with standard-of-care maintenance osimertinib. The first three dose levels will use single-patient cohorts at 50 mg/m2, 100 mg/m2 and 150 mg/m2, before progressing to larger cohorts to identify the maximum tolerated dose and an appropriate dose for further study. Between 12 and 40 patients are expected to participate in the dose-escalation stage. Following review of available safety and pharmacokinetic data, the study is expected to advance into a double-blind, randomized Phase 1b expansion stage. In this dose expansion stage, 40 patients will receive one of two RC220 dose levels in combination with osimertinib. Patients will be monitored for safety, pharmacokinetics and early signals of clinical activity, including progression-free survival, overall survival, ctDNA dynamics and changes in cancer-specific mutations. The first patient was treated by Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health in Clayton, Victoria. Additional clinical trial sites are expected to open in the coming months to support patient recruitment and study progress. Further details about HARNESS-1, including open and recruiting sites, are available through the Australian and New Zealand Clinical Trial Registry at www.anzctr.org.au under trial code ACTRN12626000325303. RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene, is a clinical validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional silencing of the important cancer growth regulator c-MYC.

Australian (ASX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Racura Oncology Doses First Patient in Harness-1 Phase 1A/B Trial of Rc220 in Combination with Osimertinib for Egfr-Mutant Non-Small Cell Lung Cancer

MSB: FDA Pathway And Trial Progress Will Drive Future Upside Potential

HLS: Potential Agilex Sale And Revised Assumptions Will Shape Future Outlook

TLX: Upcoming FDA Decisions Are Expected To Drive Future Upside

PME: Record Contracts And Index Removal Will Shape Future Returns

CSL: Cost Cuts And Capacity Expansion Will Support Long Term Earnings Recovery

Artrya Wins FDA Clearance and US Medicare Payment for Salix AI Heart Imaging Platform

Ansell Limited Announces Chief Financial Officer Changes

RHC: UK Exit Speculation And Dividend Outlook Will Support Future Upside

4DMedical (ASX:4DX) Shares Could Be 59.1% Undervalued After Philips Webinar Interest

SHL: Companion Diagnostics Partnership And Dividend Will Support Share Price Re Rating

Sigma Healthcare Abandons Boots Takeover Talks

PNV: Refined Cash Flow Assumptions Will Support Steady Outlook And Balanced Upside Potential

Investor sentiment improves as stock rises 17%

New minor risk - Insider selling

CEO, MD & Executive Director recently sold AU$1.1m worth of stock